Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Renewcell was a Swedish industrial biotechnology company specializing in the chemical recycling of textile waste into high-quality dissolving pulp. The company's proprietary technology allowed for the transformation of cotton and other cellulosic fibers into a branded material called Circulose, which could be used by fiber producers to create new virgin-quality textile fibers. Despite establishing a large-scale commercial plant (Renewcell 1) and partnering with major fashion brands like H&M and Zara, the company faced significant liquidity challenges and filed for bankruptcy in early 2024. In June 2024, the company's assets and operations were acquired by the investment firm Altor, which intends to continue the business under the name Circulose.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Renewcell.